Randomized trial reveals Bifidobacterium lactis 832 reduces colitis severity in mice, suggesting probiotic potential for IBD treatment.
Key Points
This study aims to investigate the protective effects of Bifidobacterium animalis subsp. lactis 832 on DSS-induced colitis in mice and understand its mechanisms.
Used a murine model of DSS-induced colitis
Administered B. lactis 832 and evaluated colitis severity
Conducted metabolomic analysis to assess phospholipid metabolism
B. lactis 832 treatment reduced colitis severity with p < 0.05, evidenced by less weight loss and lower DAI
Decreased levels of pro-inflammatory cytokines and increased Il10 expression with p < 0.05
Enhanced intestinal phospholipid metabolism was observed, specifically increasing PE and PC levels, with protective effects confirmed by p < 0.05 for PE or PC supplementation